Gilead Sciences, Inc.
FXR (NR1H4) MODULATING COMPOUNDS

Last updated:

Abstract:

The present disclosure relates generally to compounds that bind to FXR and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

Status:
Application
Type:

Utility

Filling date:

24 Nov 2021

Issue date:

30 Jun 2022